Engineered Staphylococcus auricularis Cas9 with high‐fidelity
The FASEB Journal · 2023
DOI: 10.1096/fj.202202132rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Nan Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Staphylococcal Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
CRISPR‐Cas9 is a versatile gene editing tool with a broad application of basic research and clinical therapeutics. However, the potential impact caused by off‐target effects remains a critical bottleneck. The small Cas9 ortholog from Staphylococcus auricularis (SauriCas9) was identified, which recognizes a 5′‐NNGG‐3′ protospacer adjacent motif (PAM), exhibiting high activity for genome editing. Recently, we also reported enhanced‐fidelity Staphylococcus aureus Cas9 (efSaCas9), which harbors a single mutation N260D. Protein sequence alignment revealed that SauriCas9 has 62.4% sequence identity with SaCas9. Because SauriCas9 is more flexible in recognizing the target sequence with PAM of 5′‐NNGG‐3′ than SaCas9 of 5′‐NNGRRT‐3′ PAM, we sought to test whether key mutation(N260D) or adjacent residue mutation in efSaCas9 can be appliable to SauriCas9. With this concept, two engineered SauriCas9 variants (SauriCas9‐HF1, harboring the N269D mutation; SauriCas9‐HF2, harboring the D270N mutation) dramatically improved targeting specificity by targeted deep sequencing and GUIDE‐seq. At certain sites, reduced off‐target effects (approximately 61.6‐ and 111.9‐fold improvements) of SauriCas9‐HF2 compared with wild‐type SauriCas9 were observed. Overall, two identified SauriCas9 variants (SauriCas9‐HF1 and SauriCas9‐HF2) expand the utility of the CRISPR toolkit for research and therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China.
- Key Laboratory of Veterinary Chemical Drugs and Pharmaceutics, Ministry of Agriculture and Rural Affairs, Shanghai, China.
ORCID-Profile: Nan Wei, Lu Shang, Jing Liu, Yingchun Liu, Fayu Yang, Feng Gu
Förderung
- National Natural Science Foundation of China (NSFC)
Zitieren
APA
Wei, N., Shang, L., Liu, J., Wang, M., Liu, Y., Zhu, C., Fei, C., Zhang, L., Yang, F., & Gu, F. (2023). Engineered Staphylococcus auricularis Cas9 with high‐fidelity. The FASEB Journal. https://doi.org/10.1096/fj.202202132rr
Vancouver
Wei N, Shang L, Liu J, Wang M, Liu Y, Zhu C, et al. Engineered Staphylococcus auricularis Cas9 with high‐fidelity. The FASEB Journal. 2023. doi:10.1096/fj.202202132rr
BibTeX
@article{Wei2023,
author = {Wei, Nan and Shang, Lu and Liu, Jing and Wang, Mi and Liu, Yingchun and Zhu, Chuangang and Fei, Chenzhong and Zhang, Lifang and Yang, Fayu and Gu, Feng},
title = {Engineered Staphylococcus auricularis Cas9 with high‐fidelity},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202202132rr}
}
EUVIMED